氨甲环酸在泌尿外科手术中的安全性与疗效:POISE-3随机对照试验结果
POISE-3试验的预设分析纳入1124例接受泌尿外科手术且具出血和心血管风险的患者,随机接受氨甲环酸(TXA)或安慰剂。TXA组大出血发生率低于安慰剂组(6.1% vs 9.5%,HR=0.63,95%CI 0.41-0.97),但30天血栓复合终点无显著差异(12.1% vs 10.9%,HR=1.12,95%CI 0.79-1.58)。结论支持在高出血风险泌尿外科手术中围术期使用TXA。
要点
- TXA组大出血风险显著低于安慰剂组(HR=0.63,95%CI 0.41-0.97)。
- 30天血栓复合终点两组无显著差异(HR=1.12,95%CI 0.79-1.58)。
- 出血高风险泌尿外科手术可考虑围术期使用TXA。
核心结论
- TXA减少泌尿外科手术患者的大出血,支持围术期使用,尤其出血风险高时。
研究设计与样本
- POISE-3为国际随机安慰剂对照试验的预设分析,纳入1124例接受泌尿外科手术且具出血和心血管风险因素的患者。
- 参与者随机接受TXA(手术开始和结束时各1g静脉推注)或安慰剂。
主要发现
- 30天出血复合终点TXA组45例(8.1%),安慰剂组62例(10.9%),HR=0.73,95%CI 0.50-1.07。
- 大出血TXA组34例(6.1%),安慰剂组54例(9.5%),HR=0.63,95%CI 0.41-0.97。
- 30天血栓复合终点TXA组67例(12.1%),安慰剂组62例(10.9%),HR=1.12,95%CI 0.79-1.58。
- MINS分别为62例与58例,卒中均为2例,VTE均为3例。
- 未发现手术方式、癌症状态或近期抗血栓药物使用与TXA效果的交互作用。
临床怎么用
- 对出血风险高的泌尿外科手术患者,可考虑围术期使用TXA以减少大出血。
- 使用TXA时应关注血栓事件,但本分析未显示血栓复合终点显著增加。
局限性
- 患者重要的血栓事件数量少,限制了对卒中和VTE估计的精确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Perioperative bleeding is common. Evidence for tranexamic acid (TXA) in urology remains limited and conflicting, and major urologic guidelines provide no recommendations. In an a priori planned analysis, we evaluated TXA among patients undergoing urologic surgery in POISE-3. METHODS: POISE-3 was an international randomized trial of patients undergoing surgery with bleeding and cardiovascular risk factors. Participants received TXA (1 g intravenous bolus at surgery start and end) or placebo. The primary efficacy outcome was a 30-day bleeding composite (life-threatening/major/critical organ), and the primary safety outcome was a 30-day thrombosis composite (myocardial injury after noncardiac surgery [MINS], nonhemorrhagic stroke, peripheral arterial thrombosis, or symptomatic proximal venous thromboembolism [VTE]). KEY FINDINGS AND LIMITATIONS: Among 1124 urologic participants (556 TXA and 568 placebo), 489 had laparoscopic/robotic, 360 open, 244 transurethral, and 31 percutaneous surgery. The composite bleeding outcome occurred in 45 (8.1%) with TXA and in 62 (10.9%) with placebo (hazard ratio [HR] = 0.73, 95% confidence interval [CI] = 0.50-1.07). Major bleeding occurred in 34 (6.1%) with TXA and in 54 (9.5%) with placebo (HR = 0.63, 95% CI = 0.41-0.97). The composite safety outcome occurred in 67 (12.1%) with TXA and in 62 (10.9%) with placebo (HR = 1.12, 95% CI = 0.79-1.58; MINS: 62 vs 58; strokes: 2 vs 2; VTEs: 3 vs 3). We identified no interactions by surgical approach, cancer status, or recent antithrombotic usage. Patient-important thrombotic events were few, limiting precision for stroke and VTE estimates. CONCLUSIONS AND CLINICAL IMPLICATIONS: TXA reduced major bleeding and supports perioperative use in urologic surgery, especially when the bleeding risk is high.
引用
- Tikkinen KAO, Marcucci M, Halme ALE, et al. Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial. Eur Urol. 2026. PMID: 42020258. doi:10.1016/j.eururo.2026.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。